相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial
Antonino Tuttolomondo et al.
CARDIOVASCULAR DIABETOLOGY (2021)
A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study
Masaru Kitazawa et al.
DIABETES OBESITY & METABOLISM (2021)
SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review
Carlos Escobar et al.
DIABETIC MEDICINE (2021)
Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials
Desye Gebrie et al.
SCIENTIFIC REPORTS (2021)
The Anti-inflammatory and Proangiogenic Properties of High-Density Lipoproteins: An Emerging Role in Diabetic Wound Healing
Zahra Lotfollahi et al.
ADVANCES IN WOUND CARE (2021)
Glucose-Lowering Medications and Cardiovascular Outcomes
Madhan Shanmugasundaram et al.
CURRENT CARDIOLOGY REPORTS (2021)
Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Peyman Nowrouzi-Sohrabi et al.
FRONTIERS IN PHARMACOLOGY (2021)
Glycation of HDL Polymerizes Apolipoprotein M and Attenuates Its Capacity to Bind to Sphingosine 1-Phosphate
Tamaki Kobayashi et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2021)
Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis
Walter Masson et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Association between nitrated lipoproteins and vascular function in type 2 diabetes
Ajibola Adedayo et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2021)
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
Ayako Fuchigami et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Dysfunctional High-Density Lipoproteins Are Associated With a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk A Nested Case-Control Study
Maria Trinidad Soria-Florido et al.
CIRCULATION (2020)
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
Shizuya Yamashita et al.
CURRENT ATHEROSCLEROSIS REPORTS (2020)
Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Rhys Williams et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
Importance of paraoxonase 1 (PON1) as an antioxidant and antiatherogenic enzyme in the cardiovascular complications of type 2 diabetes: Genotypic and phenotypic evaluation
Yasaman Shokri et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present)
Ichiro Takada et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial
Venu Menon et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Glycation of HDL blunts its anti-inflammatory and cholesterol efflux capacities in vitro, but has no effect in poorly controlled type 1 diabetes subjects
Diego Gomes Kjerulf et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2020)
Incretin drugs effect on epigenetic machinery: New potential therapeutic implications in preventing vascular diabetic complications
Lucia Scisciola et al.
FASEB JOURNAL (2020)
Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials
Adriana Sanchez-Garcia et al.
PHARMACOLOGICAL RESEARCH (2020)
Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
Mark P. Metzinger et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
HDL cholesterol efflux capacity is inversely associated with subclinical cardiovascular risk markers in young adults: The cardiovascular risk in Young Finns study
Monika Hunjadi et al.
SCIENTIFIC REPORTS (2020)
Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial
Ikaro Breder et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2020)
Structure-function relationships of HDL in diabetes and coronary heart disease
Mathias Cardner et al.
JCI INSIGHT (2020)
Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus
Robin P. F. Dullaart et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events JACC Review Topic of the Week
Jane Armitage et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis
Sarah A. Aroner et al.
DIABETOLOGIA (2019)
HDL (High-Density Lipoprotein) Cholesterol Efflux Capacity Is Associated With Incident Cardiovascular Disease in the General Population A Case-Control Study From the PREVEND Cohort
Sanam Ebtehaj et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature
Anna Solini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
Tamara Y. Milder et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Glycation Reduces the Stability of ApoAI and Increases HDL Dysfunction in Diet-Controlled Type 2 Diabetes
Sangeeta R. Kashyap et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2018)
High-density Lipoprotein (HDL) Dysfunction and the Future of HDL
Sibel Ertek
CURRENT VASCULAR PHARMACOLOGY (2018)
Epigenetic effects of metformin: From molecular mechanisms to clinical implications
Stephanie Claire Bridgeman et al.
DIABETES OBESITY & METABOLISM (2018)
Abnormalities in the relationship of paraoxonase 1 with HDL and apolipoprotein A1 and their possible connection to HDL dysfunctionality in type 2 diabetes
Alena Viktorinova et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications
Nathan K. P. Wong et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Hidenori Arai et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2018)
Type 2 diabetes is associated with loss of HDL endothelium protective functions
Tomas Vaisar et al.
PLOS ONE (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Effect of metformin monotherapy on serum lipid profile in statin-naive individuals with newly diagnosed type 2 diabetes mellitus: a cohort study
Szu Han Lin et al.
PEERJ (2018)
SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
Sempastian Filippas-Ntekouan et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Daniel S. Hsia et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2017)
Clinical relevance of epigenetics in the onset and management of type 2 diabetes mellitus
Linda Sommese et al.
EPIGENETICS (2017)
Serum amyloid A enrichment impairs the anti-inflammatory ability of HDL from diabetic nephropathy patients
Jing Yan Mao et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
Seon-Ah Cha et al.
LIPIDS IN HEALTH AND DISEASE (2017)
Apolipoprotein status in type 2 diabetes mellitus and its complications
Puhong Zhang et al.
MOLECULAR MEDICINE REPORTS (2017)
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
A. Michael Lincoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease
L. Bowman et al.
JOURNAL OF VASCULAR SURGERY (2017)
HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial
Ruth Blanco-Rojo et al.
SCIENTIFIC REPORTS (2017)
Plasma levels of Apolipoprotein A1 and Lecithin: Cholesterol Acyltransferase in type 2 diabetes mellitus: Correlations with haptoglobin phenotypes
Samir Awadallah et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2017)
The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation
Sanam Ebtehaj et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Pre-β1 HDL in type 2 diabetes mellitus
S. W. Shiu et al.
ATHEROSCLEROSIS (2017)
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial
Stephen J. Nicholls et al.
ATHEROSCLEROSIS (2017)
HDL-Targeting Therapeutics: Past, Present and Future
Emile Zakiev et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
Gian Paolo Fadini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
L. Bowman et al.
AMERICAN HEART JOURNAL (2017)
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
Toshiyuki Hayashi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus-Brief Report
Johanna Apro et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection
Jonas W. Brinck et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial
Fumiyoshi Tsunoda et al.
ATHEROSCLEROSIS (2016)
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
Shun Ishibashi et al.
ATHEROSCLEROSIS (2016)
Clinical Update: Cardiovascular Disease in Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations
Cecilia C. Low Wang et al.
CIRCULATION (2016)
The Effects of Type 2 Diabetes on Lipoprotein Composition and Arterial Stiffness in Male Youth (vol 62, pg 2958, 2013)
Scott M. Gordon et al.
DIABETES (2016)
Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative
Giuseppina T. Russo et al.
DIABETES CARE (2016)
= METFORMIN:NONGLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS
Abeer Anabtawi et al.
ENDOCRINE PRACTICE (2016)
Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes
Ida Azizkhanian et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Anti-apolipoprotein A-1 autoantibodies as risk biomarker for cardiovascular diseases in type 2 diabetes mellitus
Dalia El-Lebedy et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Fibrates for primary prevention of cardiovascular disease events
Tobias Jakob et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
HDL cholesterol as a predictor for the incidence of lower extremity amputation and wound-related death in patients with diabetic foot ulcers
Kazuki Ikura et al.
ATHEROSCLEROSIS (2015)
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients
Luis Masana et al.
ATHEROSCLEROSIS (2015)
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
Lawrence Blonde et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials
Yi Ding et al.
CLINICAL NUTRITION (2015)
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
Feng Sun et al.
CLINICAL THERAPEUTICS (2015)
Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL
Patrick M. Hutchins et al.
CURRENT OPINION IN LIPIDOLOGY (2015)
HDL Cholesterol and Risk of Type 2 Diabetes: A Mendelian Randomization Study
Christiane L. Haase et al.
DIABETES (2015)
In Type 2 Diabetes Mellitus Glycated Albumin Alters Macrophage Gene Expression Impairing ABCA1-Mediated Cholesterol Efflux
Adriana Machado-Lima et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study
Danish Saleheen et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control
Harold E. Bays et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2015)
Effect of Niacin on High-Density Lipoprotein Apolipoprotein A-I Kinetics in Statin-Treated Patients With Type 2 Diabetes Mellitus
Jing Pang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality
Marcin Barylski et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Subfractions and Subpopulations of HDL: An Update
M. Rizzo et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial
Peter E. Linz et al.
DIABETES CARE (2014)
Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes
Michela Triolo et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2014)
Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes
Hussein N. Yassine et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Markers of Systemic Inflammation and Apo-AI Containing HDL Subpopulations in Women with and without Diabetes
Giuseppina T. Russo et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2014)
Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: Impact on small HDL particles
Marcus Stahlman et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2013)
Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients
Guido Franceschini et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2013)
The Addition of Niacin to Statin Therapy Improves High-Density Lipoprotein Cholesterol Levels But Not Metrics of Functionality
Amit V. Khera et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Francisco A. Monsalve et al.
MEDIATORS OF INFLAMMATION (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials
Matteo Monami et al.
ADVANCES IN THERAPY (2012)
Pancreatic β-cell function relates positively to HDL functionality in well-controlled Type 2 diabetes mellitus
Robin P. F. Dullaart et al.
ATHEROSCLEROSIS (2012)
Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis
Camelia S. Stancu et al.
CELL AND TISSUE RESEARCH (2012)
Genetic Predisposition to Dyslipidemia and Type 2 Diabetes Risk in Two Prospective Cohorts
Qibin Qi et al.
DIABETES (2012)
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk
A. F. H. Stalenhoef et al.
DIABETES OBESITY & METABOLISM (2012)
Nonenzymatic glycation of high-density lipoprotein impairs its anti-inflammatory effects in innate immunity
Donghui Liu et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2012)
Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models
H. Low et al.
DIABETOLOGIA (2012)
High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells
Bing Pan et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Myeloperoxidase Targets Apolipoprotein A-I, the Major High Density Lipoprotein Protein, for Site-Specific Oxidation in Human Atherosclerotic Lesions
Baohai Shao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells
Lin-Hua Zhang et al.
JOURNAL OF LIPID RESEARCH (2012)
The emerging role of HDL in glucose metabolism
Brian G. Drew et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
Aneta Otocka-Kmiecik et al.
PROGRESS IN LIPID RESEARCH (2012)
Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia
Sandrine Caron et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: A FIELD substudy
Marianna Maranghi et al.
ATHEROSCLEROSIS (2011)
Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
Philip J. Barter et al.
CIRCULATION (2011)
Anti-inflammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 Diabetes
Cecilia Morgantini et al.
DIABETES (2011)
Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus
Hong Chang Tan et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Causes and Consequences of Low Levels of High Density Lipoproteins in Patients with Diabetes
Philip J. Barter
DIABETES & METABOLISM JOURNAL (2011)
Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I
Estelle Nobecourt et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy
Sajoscha A. Sorrentino et al.
CIRCULATION (2010)
Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women
Samia Mora et al.
DIABETES (2010)
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus - A pooled meta-analysis of randomized placebo-controlled clinical trials
Sandeep A. Saha et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2010)
Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export
Baohai Shao et al.
JOURNAL OF LIPID RESEARCH (2010)
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Lecithin: Cholesterol Acyltransferase, High-Density Lipoproteins, and Atheroprotection in Humans
Laura Calabresi et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus
Brian G. Drew et al.
CIRCULATION (2009)
ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan
Anne Hiukka et al.
DIABETES (2009)
Parallel increase of plasma apoproteins C-II and C-III in Type 2 diabetic patients
S. Beliard et al.
DIABETIC MEDICINE (2009)
Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
Robert R. Henry et al.
LANCET (2009)
Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
Jose W. A. van der Hoorn et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Nicotinic acid: an old drug with a promising future
E. T. Bodor et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Why Is HDL Functionally Deficient in Type 2 Diabetes?
Anatol Kontush et al.
CURRENT DIABETES REPORTS (2008)
Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides
M. Mastorikou et al.
DIABETIC MEDICINE (2008)
Determinants of leukocyte adenosine triphosphate-binding cassette transporter G1 gene expression in type 2 diabetes mellitus
Huali Zhou et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2008)
On the search for glycated lipoprotein ApoA-I in the plasma of diabetic and nephropathic patients
Annunziata Lapolla et al.
JOURNAL OF MASS SPECTROMETRY (2008)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Increased phospholipid transfer protein activity associated with the impaired cellular cholesterol efflux in type 2 diabetic subjects with coronary artery disease
Nebil Attia et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2007)
High-density lipoprotein as a therapeutic target - A systematic review
Inder M. Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Torcetrapib and atherosclerosis: what happened and where do we go from here?
Peter P. Toth
FUTURE LIPIDOLOGY (2007)
Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo
Rabea Asleh et al.
CIRCULATION RESEARCH (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor
Angela M. Whetzel et al.
CIRCULATION RESEARCH (2006)
Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation
L Persegol et al.
DIABETOLOGIA (2006)
Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus: The FIELD study, a randomised controlled trial
A. Keech
ATHEROSCLEROSIS SUPPLEMENTS (2006)
Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis
Anatol Kontush et al.
PHARMACOLOGICAL REVIEWS (2006)
Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes:: relationship to elevated oxidative stress and hyperglycaemia
E Nobécourt et al.
DIABETOLOGIA (2005)
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds - A meta-analysis of randomized controlled trials
RS Birjmohun et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Circulating levels of nitrated apolipoprotein A-I are increased in type 2 diabetic patients
R Hermo et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2005)
The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes
JB Buse et al.
DIABETES OBESITY & METABOLISM (2004)
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease
LM Zheng et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus
T Kujiraoka et al.
JOURNAL OF LIPID RESEARCH (2003)
Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance
WT Garvey et al.
DIABETES (2003)
Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The strong heart study
AP Levy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin-dependent diabetics with coronary artery disease
MC Bakogianni et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2001)
Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy
B Mackness et al.
CLINICAL SCIENCE (2000)
Glycation impairs high-density lipoprotein function
CC Hedrick et al.
DIABETOLOGIA (2000)
分享论文
